<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

2 min read

The Market Collapses: Q220 US Surgical Matrices Recap

9/14/20 9:17 AM

Q220 US Surgical Matrices HeaderThe US Surgical Matrices Market collapsed in Q220, achieving sales of $227.3MM, off -39.4% YoY, as the effects of COVID-19 became evident with many delayed or canceled surgeries. The problems were evident everywhere, where Breast Matrices dropped -46.4 YoY to $69.6MM in Q220, while Hernia Matrices fell off -35.7% YoY to $157.7MM.

With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Surgical Matrices Market yielded -39.4% YoY, according to BioMedGPS’ SmartTRAK Financial DashboardAllergan* held on to its lead despite the effects of the pandemic, giving back -46.9%. Becton Dickinson* (BD) lost less than Allergan, declining -36.8%. However, Medtronic* announced that its hernia business was recovering faster than it expected.

Among the many topics covered in the comprehensive Q220 US Surgical Matrices Market Recap* are:

  • Complete US Surgical Matrices Market Overview
  • COVID-19 Crushes The US Surgical Matrices Market
  • US Breast Matrices: Surgery Delays Prove Too Much To Overcome
  • US Hernia Repair Matrices: Giving Back Earlier Gains
  • Other Q220 events in the US Surgical Matrices Market

The US Surgical Matrices market flopped in both the Breast Reconstruction and Hernia Repair segments, with both segments experiencing the full impact of elective surgeries delayed due to the pandemic. For Q220, the Breast segment waned -46.4% YoY to ...

Read the entire Q220 US Surgical Matrices Market Recap including news, data, charts, company revenues and analysis*

*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.

Learn More

Doug Devens
Written by Doug Devens

20 years of diverse medical device experience, including leading companies 3M, Coloplast and Boston Scientific, along with emerging companies. Leadership experience in product development, including championing the process for voice of customer and concept feedback sessions with key thought leaders.

    Recent Articles